[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Second Affiliated Hospital of Nanchang University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":611},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,49,74,103,135,163,187,208,226,249,271,289,309,328,351,375,399,421,441,461,486,511,540,563,584],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100644884","clinical-risk-score-prediction-for-risk-of-dementia-among-late-life-population-with-depression-100644884",false,"NCT07676851","Clinical Risk Score Prediction for Risk of Dementia Among Late-life Population With Depression","Development of a Clinical Risk Score Prediction Tool for 5-, 9-, and 13-year Risk of Dementia Among Late-life Population With Depression: a Longitudinal Cohort Study","Inclusion Criteria:\n\n* Adults aged ≥50 years.\n* A diagnosis of depression clearly recorded by a clinician in the electronic medical record at baseline (based on structured or unstructured diagnostic documentation formed through routine clinical practice).\n* Complete baseline electronic medical record data available, including at least demographic information (age, sex), clinical diagnoses, comorbidities, and medication records.\n* At least one follow-up record available in the electronic medical record system to enable determination of incident dementia outcomes.\n* Informed consent provided for the use of routine medical data for this research analysis.\n\nExclusion Criteria:\n\n* Any type of dementia diagnosis recorded in the electronic medical record at baseline (including Alzheimer's disease, vascular dementia, and other types of dementia).\n* Medical record documentation indicating that the diagnosis of dementia preceded the diagnosis of depression, or an inability to clearly determine the chronological order of the two diagnoses.\n* Presence of other neurological diseases at baseline that may independently cause severe cognitive impairment (e.g., Parkinson's disease, multiple sclerosis, brain tumor, normal pressure hydrocephalus).\n* Missing key baseline electronic medical record data that would preclude subsequent risk model analysis.\n* Incomplete follow-up information or inability to clearly confirm incident dementia outcomes through the electronic medical record system.\n* Refusal to participate in the study or withdrawal of informed consent.",true,"ALL","50 Years",{"count":21,"type":22},44,"ESTIMATED","13 Years","OBSERVATIONAL","The goal of this observational study is to learn about the ability of a point risk score prediction model, developed using electronic medical record data, to predict the risk of progression from geriatric depression to dementia in older Chinese adults. The main questions it aims to answer are:\n\nDoes a higher point risk score increase the risk of developing dementia in older adults with depression?\n\nWhat is the accuracy of the point risk score prediction model in identifying individuals at high risk of dementia among older adults with depression?\n\nParticipants will receive their usual medical care as they normally would. No new treatments, tests, or procedures will be performed specifically for this study. The research team will collect data from their electronic medical records, including depression diagnoses, dementia diagnoses, comorbidities, medication records, and follow-up information. The point risk score will be calculated based on these routinely collected clinical data.",[27,28,29,30,31,32,33,34,35],"Alzheimer Dementia (AD)","Dementia","Late Life Depression (LLD)","Risk Scores","Prediction","Chinese Population","Obs e r","Observational Cohort Study","External Validation","RECRUITING","2026-06-24",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":40},"2006-06-01",{"date":44,"type":22},"2030-06-30",{"name":46,"class":47},"Second Affiliated Hospital of Nanchang University","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100603038","phase-2-sfrttislelizumabplatinum-chemotherapy-for-unresectable-stage-iii-nsclc-100603038","NCT07131319","SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","Spatially Fractionated Radiotherapy (SFRT) Synchronized With Tislelizumab Plus Platinum-based Dual-agent Chemotherapy for Induction Treatment of Initially Unresectable Stage Ⅲ Non-small Cell Lung Cancer: A Clinical Study","Inclusion Criteria:\n\n* The patient has histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) that is deemed unresectable after discussion in the multidisciplinary team (MDT), which is classified as T3-4N1-2M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC).\n\nExclusion Criteria:\n\n* Has participated in another clinical study using research products within the past 3 weeks.","18 Years","85 Years",{"count":59,"type":22},30,"INTERVENTIONAL",[62,63],"PHASE2","PHASE3","The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are:\n\nWill spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection rate of patients with initially unresectable stage Ⅲ non-small cell lung cancer? What adverse reactions will patients experience when receiving spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment?",[66],"Non-Small Cell Lung Cancer",{"date":68,"type":40},"2026-06-25",{"date":70,"type":40},"2025-04-21",{"date":72,"type":22},"2028-12-31",{"name":46,"class":47},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":60,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":48},"100641524","phase-1-vebreltinib-plus-furmonertinib-in-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer-and-high-pd-l1-expression-100641524","NCT07655622","Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression","A Single-arm, Phase I\u002FII Trial Aimed to Evaluate the Efficacy and Safety of Vebreltinib Plus Furmonertinb as First-line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring EGFR Mutations and High PD-L1 Expression","DUAL-THRUST","Inclusion Criteria:\n\n1. Voluntarily agree to participate in this study and sign a written informed consent form\n2. Age ≥18 years and ≤75 years, regardless of gender\n3. Histologically or cytologically confirmed locally advanced (stage IIIB-IIIC), metastatic, or recurrent (stage IV) non-small cell lung cancer, not amenable to surgical resection and definitive concurrent chemoradiotherapy\n4. No prior systemic antineoplastic therapy for advanced\u002Fmetastatic disease Histologically or cytologically confirmed EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R point mutation)\n5. Central laboratory-confirmed PD-L1 Tumor Proportion Score (TPS) ≥50%\n6. At least one measurable target lesion according to RECIST v1.1 criteria\n7. Asymptomatic or locally treated stable brain metastases are allowed.\n8. ECOG performance status 0-1\n9. Expected survival ≥3 months\n10. Adequate organ function\n\nExclusion Criteria:\n\n1. Histological type of small cell lung cancer or mixed small cell lung cancer\n2. Prior treatment with any EGFR-TKI or MET-TKI\n3. Presence of ALK fusion positive or ROS1 fusion positive\n4. Other active malignant tumors (except completely resected carcinoma in situ, basal cell or squamous cell skin cancer, or tumors with no recurrence for ≥3 years after curative treatment)\n5. Major surgery within 4 weeks before first dose (except brain metastasis resection, which requires ≥2 weeks); thoracoscopic biopsy or mediastinoscopy is excluded (requires ≥1 week)\n6. Require use of strong CYP3A4 inhibitors or inducers within 1 week before first dose or during the study\n7. Uncontrolled systemic diseases\n8. Cardiac dysfunction: QTcF \\>470ms (average of three ECGs) at screening; NYHA functional class ≥3 or LVEF \\\u003C50%\n9. Dysphagia, active digestive system disease, or history of major gastrointestinal surgery that may affect drug absorption\n10. History of acute or chronic pancreatitis or pancreatic surgery\n11. Other conditions deemed unsuitable for participation by the investigator","75 Years",{"count":84,"type":22},45,[86,62],"PHASE1","This is a single-arm, exploratory phase Ib\u002FII study with a seamless design to evaluate the safety and efficacy of Vebreltinib combined with furmonertinib as first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations (exon 19 deletion or L858R) and PD-L1 TPS ≥50%.\n\nIn the phase Ib part, 12-16 patients will be enrolled to compare the safety and early efficacy of Vebreltinib 100mg BID versus 150mg BID in combination with furmonertinib 80mg QD, and to determine the recommended phase II dose (RP2D).\n\nIn the phase II part, 37 patients (including evaluable patients from the RP2D cohort in phase Ib) will receive treatment at the RP2D. The primary endpoint is investigator-assessed median progression-free survival (PFS). Secondary endpoints include objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Exploratory endpoints will analyze the correlation between baseline MET abnormalities and treatment efficacy.",[89],"Non-Small-Cell Lung Cancer",[91,92,93,94,89],"EGFR mutation","PD-L1 high expression","Vebreltinib","Furmonertinib","2026-06-17",{"date":97,"type":40},"2026-06-18",{"date":99,"type":22},"2026-07-03",{"date":101,"type":22},"2029-06-03",{"name":46,"class":47},{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":111,"targetDuration":4,"studyType":60,"phases":113,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100639019","early-lumbar-drainage-for-intraventricular-hemorrhage-100639019","NCT07625449","Early Lumbar Drainage for Intraventricular Hemorrhage","Effectiveness and Safety of Early Lumbar Drainage in the Treatment of Ventricular Hemorrhage: the LD-IVH Randomized Controlled Trial","LD-IVH","Inclusion Criteria:\n\n* Aged 18 to 85 years old, no limitation on gender.\n* First-ever intracerebral hemorrhage confirmed by CT\u002FMRI, accompanied by third and\u002For fourth intraventricular hemorrhage, requiring external ventricular drainage.\n* Baseline hemorrhage volume less than 30 mL, with stable clinical condition before randomization.\n* External ventricular drainage performed within 48 hours of symptom onset.\n* Randomization completed within 24 hours after EVD placement.\n* Pre-morbid modified Rankin Scale (mRS) score of 0 or 1.\n* Written informed consent obtained from the participant or their legally authorized representative.\n\nExclusion Criteria:\n\n* Suspected or untreated ruptured intracranial aneurysm, arteriovenous malformation (AVM), or intracranial tumor, unless excluded by vascular imaging. Previously treated aneurysm or AVM must have been completed at least 3 months prior to enrollment.\n* Choroidal vascular malformation or moyamoya disease.\n\n  • Long-term oral anticoagulant use, persistent coagulation dysfunction, or known allergy to urokinase.\n* Platelet count \\\u003C 100×10⁹\u002FL or INR \\> 1.4.\n* Absolute contraindications to lumbar cistern drainage or external ventricular drainage, such as cerebral hernia or infection at the puncture site.\n* Infratentorial hemorrhage volume ≥ 10 mL.\n* Thalamic hemorrhage ≥ 10 mL, or accompanied by midbrain extension, oculomotor nerve palsy, or fixed dilated pupil.\n* Hemiplegia with muscle strength grade 0 or 1.\n* Active bleeding in the gastrointestinal, genitourinary, or respiratory system.\n* Multiple ecchymoses or petechiae suggesting a bleeding tendency.\n* Expected survival time less than 6 months.\n* Severe, untreatable concomitant systemic diseases.\n* Pregnancy.\n* Participation in other interventional clinical trials within 30 days prior to randomization.\n* Any other condition deemed inappropriate for enrollment by the investigator(s).",{"count":112,"type":22},392,[114],"NA","This is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial comparing the addition of early lumbar drainage to standard care in patients with intraventricular hemorrhage (IVH) in China. The primary objective is to evaluate whether early lumbar drainage improves long-term functional outcomes at 180 days, as measured by the modified Rankin Scale (mRS), and reduces complications in patients treated with external ventricular drainage (EVD) and intrathecal urokinase.",[117,118],"Intraventricular Hemorrhage","Cerebral Hemorrhage",[117,120,121,122,123,124],"Lumbar Drainage","External Ventricular Drainage","Urokinase","PROBE design","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-06-03",{"date":128,"type":40},"2026-06-04",{"date":130,"type":22},"2026-06",{"date":132,"type":22},"2029-10",{"name":46,"class":47},29,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":82,"enrollmentInfo":143,"targetDuration":4,"studyType":60,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":48},"100638353","deep-sedation-vs-general-anesthesia-for-pulsed-field-ablation-in-atrial-fibrillation-100638353","NCT07621432","Deep Sedation vs. General Anesthesia for Pulsed Field Ablation in Atrial Fibrillation","A Study on the Safety and Efficacy of Deep Sedation With Dexmedetomidine Combined With Remimazolam and Remifentanil Versus General Anaesthesia for Radiofrequency Ablation of Atrial Fibrillation","SAFE-PFA","Inclusion Criteria:\n\n* Age 18 to 75 years, inclusive\n* Clinically diagnosed atrial fibrillation\n* Indicated for pulsed field ablation and scheduled for pulsed field ablation catheter procedure\n* Able and willing to provide written informed consent\n* Willing to comply with study procedures and follow-up requirements\n\nExclusion Criteria:\n\n* Left atrial diameter \\>55 mm\n* Presence of left atrial thrombus detected by transesophageal echocardiography\n* Contraindications to anticoagulation therapy",{"count":144,"type":22},80,[114],"1. Research Title: A Study on the Safety and Efficacy of Deep Sedation With Dexmedetomidine Combined With Remimazolam and Remifentanil Versus General Anaesthesia for Radiofrequency Ablation of Atrial Fibrillation\n2. Research Objective: The aim of this study is to compare the safety and efficacy of deep sedation using a combination of dexmedetomidine and remimazolam versus remifentanil, and general anaesthesia, in patients undergoing pulsed electric field ablation for atrial fibrillation. Through this study, we hope to optimise the management of the perioperative period for atrial fibrillation pulse field ablation and develop a carefully designed deep sedation protocol based on modern pharmacology. This protocol will maximise patient comfort, facilitate the surgeon's procedure, and enhance the efficiency of overall healthcare resource utilisation, whilst ensuring surgical success and patient safety. Consequently, it will provide crucial anaesthetic support for the standardisation and widespread adoption of atrial fibrillation pulse field ablation technology.\n3. Study Design: Interventional clinical study\n4. Study Subjects: Patients with atrial fibrillation scheduled for catheter ablation at the Second Affiliated Hospital of Nanchang University between January 2026 and January 2027.\n5. Sample Size: N=80 patients, randomly assigned using a computer-generated random number table to the deep sedation group (n=40) or general anesthesia group (n=40) at a 1:1 ratio.\n6. Inclusion and Exclusion Criteria:\n\n   Inclusion Criteria: ① Age 18-75 years (inclusive); ② Clinically diagnosed with atrial fibrillation, indicated for pulse field ablation, and scheduled for catheter ablation; ③ Voluntarily agrees to participate in the trial and has signed informed consent; ④ Willing to comply with the trial requirements and complete the required follow-up.\n\n   Exclusion Criteria: ① Left atrial diameter \\> 55 mm; ② Transesophageal echocardiography indicates a thrombus in the left atrium; ③ Contraindications to anticoagulation\n7. Observational Indicators:(1) Baseline Data: Age, sex, BMI, type of atrial fibrillation, CHA2DS2-VASc score, hemoglobin, left atrial diameter, ejection fraction, and the prevalence of diabetes, hypertension, congestive heart failure, stroke\u002FTIA, coronary heart disease and renal impairment.(2) Surgical Data: Duration of interventional procedures, X-ray exposure, operating theatre occupancy time, success rate of acute PVI, calibration deviation rate, incidence of hypoxemia and hypotension, Numerical Rating Scale (NRS) scores for pain, and postoperative complications.\n8. Statistical Analysis: Data analysis was performed using IBM SPSS Statistics 26.0 software; continuous variables following a normal distribution are expressed as mean ± standard deviation, and comparisons between two independent samples were performed using t-tests; categorical variables are presented as frequencies and percentages, and comparisons were performed using chi-square tests; a two-sided P-value of \\\u003C0.05 was considered statistically significant.",[148],"Atrial Fibrillation (AF)",[150,151,152,153,154],"atrial fibrillation","pulse field ablation","deep sedation","general anesthesia","Catheter ablation","2026-05-31",{"date":157,"type":40},"2026-06-02",{"date":159,"type":22},"2026-05-25",{"date":161,"type":22},"2027-04-30",{"name":46,"class":47},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":17,"sex":18,"minAge":169,"maxAge":4,"enrollmentInfo":170,"targetDuration":172,"studyType":24,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":185,"leadSponsor":186,"locationsCount":48},"100640845","phenotypic-age-acceleration-phenoageaccel-for-joint-prediction-of-disease-risk-mortality-risk-life-expectancy-and-disease-free-healthspan-in-major-chronic-diseases-100640845","NCT07595094","Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases","Inclusion Criteria:\n\n* Adults aged 35-73 years old. Complete routine blood test data available at baseline to calculate Phenotypic -Age (including albumin, alkaline phosphatase, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean corpuscular volume, red cell distribution width, and white blood cell count).\n\nComplete demographic and clinical data (e.g., sex, BMI, comorbidities) available at baseline.\n\n* Consent to use routine medical data for research follow-up analysis.\n\nExclusion Criteria:\n\n* Presence of end-stage diseases (e.g., end-stage liver\u002Frenal failure) other than the major chronic diseases of interest at baseline.\n* Key baseline data missing, making Phenotypic Age calculation impossible. Incomplete follow-up information or inability to confirm outcomes (e.g., death, disease onset) via database linkage.\n* Refusal to participate in the study or withdrawal of informed consent.","35 Years",{"count":171,"type":22},2000000,"10 Years","The goal of this observational study is to learn about the ability of Phenotypic Age Acceleration (PhenoAgeAccel) to predict four key health outcomes in Chinese people with or at risk of major chronic diseases: the risk of developing new chronic diseases, the risk of dying, life expectancy, and disease-free healthspan.\n\nThe main questions this study aims to answer are:\n\n* Does higher PhenoAgeAccel increase the risk of developing major chronic diseases (including diabetes, dementia, cancer, and chronic respiratory diseases) in Chinese adults?\n* Does higher PhenoAgeAccel increase the risk of death from all causes in Chinese adults?\n* How do life expectancy and disease-free healthspan differ between people with high versus low PhenoAgeAccel?\n\nWho can take part in this study? Adults aged 35 or above years old who receive routine care at participating hospitals in China, have complete routine blood test data available, and have provided consent to use their health information for research purposes.\n\nWhat will participants go through? Participants will receive their usual medical care as they normally would. No new treatments, tests, or procedures will be performed specifically for this study. We will collect data from their medical records, including blood test results used to calculate PhenoAgeAccel, diagnoses of new diseases, and dates of death.\n\nWhat are the potential benefits? Participants will not receive direct personal benefits from taking part in this study. However, the information learned may help us better understand biological aging and improve future risk assessment and health management for people with chronic diseases.\n\nIs this study safe? Yes. This is an observational study that does not involve any new drugs, devices, or invasive procedures. All data used in the study will be de-identified and kept strictly confidential to protect participants' privacy.",[175,176,177,178,179,180,32,34],"Phenotypic Age Acceleration","Biological Aging Marker","Mortality Risk Prediction","Disease Risk Prediction","Life Expectancy","Disease-Free Healthspan","2026-05-16",{"date":183,"type":40},"2026-05-19",{"date":42,"type":40},{"date":44,"type":22},{"name":46,"class":47},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":17,"sex":18,"minAge":194,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":48},"100636822","hemorrhage-stroke-decision-making-model-based-deep-learning-brainhemoai-system-100636822","NCT07570680","Hemorrhage Stroke Decision Making Model Based Deep Learning (BrainHemoAI System)","Construction of an Integrated Intelligent Model for Spontaneous Intracerebral Hemorrhage Based on Deep Learning","Inclusion Criteria:\n\n1. Age \\>= 8 years old;\n2. Patients diagnosed with spontaneous hemorrhagic stroke based on medical history and auxiliary examinations;\n3. Received non-contrast computed tomography (NCCT) in the outpatient or emergency department;\n4. Treated in accordance with standard clinical guidelines during hospitalization;\n5. Have complete clinical data.\n\nExclusion Criteria:\n\n1. Had undergone surgical treatment in another hospital before admission;\n2. Was in a state of shock upon admission;\n3. Had severe heart, liver, or kidney dysfunction or other life-threatening systemic diseases;\n4. Died during hospitalization;\n5. Had an expected lifespan of less than six months or was unable to complete the study follow-up for other reasons.","8 Years",{"count":196,"type":22},7100,"Although hemorrhagic stroke also has the characteristics of high mortality and disability rates, and constitutes a major public health problem worldwide, there is a relative lack of in-depth research teams for hemorrhagic stroke in China. The current preoperative imaging evaluation of spontaneous cerebral hemorrhage is still limited to the traditional Tada formula, and there are subjective differences in diagnosis among different doctors, making it difficult to achieve homogenization in clinical decision-making. Hemorrhagic stroke is a common and frequently occurring disease in Jiangxi Province. Therefore, establishing a new diagnosis and treatment system focused on hemorrhagic stroke can not only fill the research gap in this field in China, improve the accuracy and homogeneity of hemorrhagic stroke diagnosis and treatment, but also promote related research progress to reduce the mortality and disability rates of this disease and improve the clinical prognosis of patients.",[199],"Hemorrhage Stroke","2026-04-29",{"date":202,"type":40},"2026-05-06",{"date":204,"type":40},"2022-09-01",{"date":206,"type":22},"2026-12-30",{"name":46,"class":47},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":60,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":48},"100636791","research-on-the-application-of-nursing-intervention-based-on-ithbc-theory-in-postoperative-self-management-of-patients-with-varicose-veins-of-the-lower-extremities-100636791","NCT07570277","Research on the Application of Nursing Intervention Based on ITHBC Theory in Postoperative Self-Management of Patients With Varicose Veins of the Lower Extremities","Inclusion Criteria:\n\n* It meets the diagnostic criteria for varicose veins of the lower extremities in the \"Chinese Guidelines for the Diagnosis and Treatment of Chronic Venous Diseases\";\n* The first surgical treatment for varicose veins of the lower extremities was received;\n* Age \\>18 years old;\n* The patient is conscious, has no language communication barriers, possesses certain reading and writing abilities, and is proficient in using intelligent devices;\n* Informed consent and voluntary participation.\n\nExclusion Criteria:\n\n* Secondary varicose veins of the lower extremities ;\n* Patients with a history of severe organ diseases or mental illness;\n* Patients with combined lower extremity arterial diseases, acute infections and malignant tumors;\n* Participate in other researchers.",{"count":215,"type":22},104,[114],"This study constructed a postoperative self-management nursing intervention program for VVLE patients based on the ITHBC theory, and explored the impact of this program on the patients' postoperative self-management ability, self-efficacy, complication rate and quality of life.",[219],"Varicose Veins",{"date":202,"type":40},{"date":222,"type":40},"2025-05-15",{"date":224,"type":22},"2026-06-01",{"name":46,"class":47},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":82,"enrollmentInfo":233,"targetDuration":4,"studyType":60,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":48},"100596156","phase-2-iparomlimab-and-tuvonralimab-combined-with-sfrt-and-definitive-chemoradiotherapy-in-locoregionally-advanced-bulky-hnscc-100596156","NCT07041788","Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC","A Prospective, Single-Arm Clinical Trial of Iparomlimab and Tuvonralimab Combined With Spatially Fractionated Radiotherapy and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Age between 18 and 75 years, both sexes eligible;\n2. Histologically confirmed head and neck squamous cell carcinoma (HNSCC), diagnosed as locoregionally advanced disease with measurable primary tumor and\u002For cervical metastatic lymph nodes \\>5 cm in maximum diameter, and deemed unresectable by surgical evaluation;\n3. Treatment-naive (no prior anti-tumor therapy);\n4. At least one measurable lesion (excluding brain metastases) per RECIST 1.1 criteria;\n5. ECOG performance status 0-1;\n6. Life expectancy ≥12 weeks;\n7. Organ function meeting the following criteria (no blood products, colony-stimulating factors, leukocyte\u002F thrombocyte\u002F erythrocyte-stimulating agents within 14 days prior to first study drug administration):\n\n   1. Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL;\n   2. Platelets ≥90×10\\^9\u002FL;\n   3. Hemoglobin ≥8 g\u002FdL;\n   4. Serum albumin ≥2.8 g\u002FdL;\n   5. Total bilirubin ≤1.5×ULN, ALT\u002FAST\u002FALP ≤2.5×ULN; if liver metastases present, ALT\u002FAST ≤5×ULN; if liver\u002Fbone metastases present, ALP ≤5×ULN;\n   6. Serum creatinine ≤1.5×ULN or creatinine clearance \\>60 mL\u002Fmin;\n   7. APTT and INR ≤1.5×ULN (patients on stable anticoagulation \\[e.g., LMWH, warfarin\\] with therapeutic INR acceptable for screening).\n8. Voluntary informed consent, good compliance, and willingness to cooperate with follow-up;\n9. Investigator determination of potential benefit.\n\nExclusion Criteria:\n\n1. Those with a history of severe immediate - type allergic reactions to any of the drugs used in this study；\n2. Within six months before screening, having any of the following conditions: myocardial infarction, severe\u002Funstable angina pectoris, coronary\u002Fperipheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism. Patients known to have coronary artery disease, congestive heart failure that doesn't meet the above criteria, or a left ventricular ejection fraction of less than 50% must have an optimally stable medical regimen as determined by the treating physician. If appropriate, a cardiologist can be consulted；\n3. Individuals who have received anti - tumor vaccines or live vaccines within four weeks before the first administration of the study drug；\n4. Patients with active autoimmune diseases or a history of autoimmune diseases that are likely to relapse. The following patients are not excluded and can proceed to further screening:\n\n   1. Those with well - controlled type 1 diabetes.\n   2. Patients with hypothyroidism that can be controlled with hormone replacement therapy alone.\n   3. People with skin diseases that do not require systemic treatment, such as vitiligo, psoriasis, and alopecia.\n   4. Any other diseases that are not expected to relapse without external triggers；\n5. Those lacking full or restricted civil capacity；\n6. Patients with physical or mental disorders who, in the investigator's opinion, are unable to fully or adequately understand the potential complications of this study；\n7. Patients with an expected survival time of less than three months；\n8. Patients with significantly reduced functions of the heart, liver, lungs, kidneys, and bone marrow；\n9. Those with a history of substance abuse or alcohol addiction；\n10. Patients whose tumor lesions invade large blood vessels, such as the internal carotid artery and jugular vein and their main branches, with a high risk of bleeding；\n11. Subjects who need systemic treatment with corticosteroids (more than 10 mg\u002Fday prednisone equivalent) or other immunosuppressants within two weeks before the first use of the study drug, except for the use of corticosteroids for local esophageal inflammation and the prevention of allergies, nausea, and vomiting. In other special cases, communication with the sponsor is required. In the absence of active autoimmune diseases, the inhalation or local use of steroids and adrenal cortical hormone replacement at a dose higher than 10 mg\u002Fday prednisone equivalent is allowed；\n12. Those with a history of immunodeficiency, including HIV - positive results, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation and allogeneic bone marrow transplantation；\n13. Pregnant or lactating female patients, as well as male or female patients who are fertile but unwilling or unable to use contraception throughout the study and for at least one year after the end of the treatment plan；\n14. Patients who, in the investigator's opinion, are not suitable for inclusion.",{"count":7,"type":22},[62],"Study Objectives\n\n1. Primary Objective:\n\n   The core aim of this study is to investigate whether the sequential approach of Spatially Fractionated Radiotherapy followed by 3 cycles of induction chemotherapy combined with Iparomlimab and Tuvonralimab, definitive chemoradiotherapy, and maintenance therapy with the Iparomlimab and Tuvonralimab can improve the 2-year event-free survival (EFS) rate in patients with locoregionally advanced bulky head and neck squamous cell carcinoma (HNSCC).\n2. Secondary Objectives:s\n\nTo analyze the impact of this integrated treatment regimen on key efficacy endpoints, including:\n\nObjective response rate (ORR), Duration of response (DoR), Distant metastasis-free survival (DMFS), Local region recurrence-free survival (LRRFS), Overall survival (OS)。 2. Study Endpoints\n\n(1) Primary Endpoint and Definition: 2-Year Event-Free Survival (EFS) Rate (2) Secondary Endpoints and Definitions:\n\n1. 2-Year Overall Survival (OS) Rate\n2. 2-Year Distant Metastasis-Free Survival (DMFS) Rate.\n3. 2-Year Local Region Recurrence-Free Survival (LRRFS) Rate.\n4. Objective Response Rate (ORR).\n5. Duration of Response (DoR).\n6. Quality of Life (QoL):\n\n   Assessed across multiple domains:\n\n   Physical Function: Measured via tools like the 6-minute walk test or ADL (Activities of Daily Living) scale.\n\n   Psychological Status: Evaluated using instruments such as HAMD (Hamilton Anxiety and Depression Scale) or MMSE (Mini-Mental State Examination).\n\n   Social Function: Assessed via social engagement questionnaires (e.g., HAQ-DI \\[Health Assessment Questionnaire-Disability Index\\]).\n\n   Spiritual Well-being: Evaluated using tools like PIL (Purpose in Life test). Clinically meaningful improvements in these domains before and after treatment define successful QoL endpoints (e.g., positive changes in physical, psychological, social, and spiritual health in cardiac patients).\n7. Safety:\n\n   The nature and severity of adverse reactions associated with the treatment.\n8. Tolerability:\n\nThe degree to which patients can endure treatment-related side effects.",[237],"Cancer",[239,240,241],"Spatially Fractionated Radiation Therapy","Ipalontilimab and Tuvorilimab","Locoregionally advance head and neck squamous cell carcinoma",{"date":243,"type":40},"2026-04-30",{"date":245,"type":22},"2026-04-28",{"date":247,"type":22},"2030-07-09",{"name":46,"class":47},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":82,"enrollmentInfo":256,"targetDuration":4,"studyType":60,"phases":257,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":48},"100588081","phase-2-sfrtsequential-hypofractionatedconventional-fractionated-rtiparomlimab-and-tuvonralimab-for-relapsedrefractory-solid-tumors-100588081","NCT06936748","SFRT+Sequential Hypofractionated\u002FConventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed\u002FRefractory Solid Tumors","A Study of Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated RT Combined With Iparomlimab and Tuvonralimab for Relapsed and Refractory Bulky Solid Tumors","Inclusion Criteria:\n\n1. Age 18-75 years, male or female.\n2. Histologically confirmed malignant tumor in the past.\n3. Disease recurrence after treatment, including local regional relapsed and distant metastasis.\n4. At least one measurable lesion with a maximum diameter greater than 6 cm, unsuitable for conventional surgery, ablation, or other treatments.\n5. ECOG: 0-2 points.\n6. Expected survival ≥3 months.\n7. Washout period of previous anti-tumor treatment \\>4 weeks.\n8. The patient agrees and signs the informed consent form.\n9. The function of vital organs meets the following requirements (no use of any blood components, cell growth factors, leukocyte boosters, platelet boosters, or anemia correction drugs within 14 days prior to the first use of the study drug):\n\n   1. Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL;\n   2. Platelets ≥90×10\\^9\u002FL;\n   3. Hemoglobin ≥8g\u002FdL;\n   4. Serum albumin ≥2.8g\u002FdL;\n   5. Total bilirubin ≤1.5×ULN, ALT, AST, and\u002For AKP ≤2.5×ULN; if liver metastasis is present, ALT and\u002For AST ≤5×ULN; if liver or bone metastasis is present, AKP ≤5×ULN;\n   6. Serum creatinine ≤1.5×ULN or creatinine clearance rate greater than 60 mL\u002Fmin;\n   7. Activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤1.5×ULN (patients on stable doses of anticoagulation therapy such as low molecular weight heparin or warfarin with INR within the expected therapeutic range can be screened).\n10. Negative pregnancy test for female subjects (for female patients of childbearing potential);\n11. The subject voluntarily joins the study, signs the informed consent form, has good compliance, and cooperates with follow-up;\n12. The investigator believes that the patient may benefit.\n\nExclusion Criteria:\n\n1. History of severe immediate hypersensitivity reaction to any of the drugs used in this study.\n2. Any of the following conditions within 6 months prior to screening: myocardial infarction, severe\u002Funstable angina pectoris, coronary\u002Fperipheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism. Patients known to have coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction \\\u003C50% must be on an optimized stable medical regimen as determined by the treating physician; consultation with a cardiologist may be appropriate if necessary.\n3. History of receiving anti-tumor vaccines or live vaccines within 4 weeks prior to the first dose of the investigational drug.\n4. Active autoimmune diseases or history of autoimmune diseases that may recur. However, patients with the following conditions are not excluded and can proceed to further screening:\n\n   1. Controlled Type 1 diabetes\n   2. Hypothyroidism (if it can be controlled with hormone replacement therapy alone)\n   3. Skin conditions that do not require systemic therapy (e.g., vitiligo, psoriasis, alopecia)\n   4. Any other condition not expected to recur without external triggering factors\n5. Lack of civil capacity or limited civil capacity.\n6. Physical or mental conditions that impair the patient's ability to fully or adequately understand the potential complications of this study, as judged by the investigator.\n7. Patients with an expected survival of less than 3 months.\n8. Patients with significantly diminished cardiac, hepatic, pulmonary, renal, and bone marrow function.\n9. Drug abuse or alcohol addiction.\n10. Tumor lesions invading major blood vessels such as the internal carotid artery and vein and their major branches, posing a high risk of bleeding.\n11. Subjects requiring systemic treatment with corticosteroids (more than 10mg\u002Fday prednisone equivalent dose) or other immunosuppressive agents within 2 weeks prior to the first use of the investigational drug, except for the use of corticosteroids for local esophageal inflammation and prevention of allergies and nausea\u002Fvomiting. Special cases need to be discussed with the sponsor. In the absence of active autoimmune disease, inhaled or topical steroids and adrenal corticosteroid replacements at doses \\>10mg\u002Fday prednisone equivalent are allowed.\n12. History of immunodeficiency, including HIV-positive status, or other acquired or congenital immunodeficiency disorders, or history of organ transplantation or allogeneic bone marrow transplantation.\n13. Pregnant or breastfeeding female patients, male or female patients of childbearing potential who are unwilling or unable to use contraception for at least 1 year after the end of the treatment protocol throughout the study period.\n14. The investigator deems the patient unsuitable for inclusion.",{"count":59,"type":22},[62],"Study Objectives Primary Objective:To evaluate the safety of SFRT followed by hypofractionated\u002Fconventional fractionated radiotherapy combined with Iparomlimab and Tuvonralimab Injection in relapsed\u002Frefractory bulky solid tumors.\n\nSecondary Objectives:To assess efficacy (objective response rate, disease control rate, progression-free survival, etc.) and identify predictive biomarkers.To explore correlations between immunologic biomarkers (e.g., PD-L1 expression, plasma IL-2\u002FIL-10) and treatment outcomes.\n\nStudy Endpoints Primary: Safety (incidence\u002Fseverity of treatment-related adverse events).\n\nSecondary:\n\nORR, DCR, DoR, mPFS, mOS Exploratory: Biomarker analysis (PD-L1, IL-2, IL-10).",[237],[261,239,262,263],"Bulky Solid Tumors","Immunotherapy","Iparomlimab and Tuvonralimab",{"date":265,"type":40},"2026-05-05",{"date":267,"type":40},"2025-06-20",{"date":269,"type":22},"2029-06-19",{"name":46,"class":47},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":82,"enrollmentInfo":278,"targetDuration":4,"studyType":60,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":48},"100558706","phase-2-olanzapine-impact-on-first-line-immunotherapy-for-advanced-egfr-negative-nsclc-100558706","NCT06554613","Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC","An Open-label, Two-arm, Multicenter, Phase II Randomized Controlled Trial Assessing the Impact of Olanzapine on the Efficacy of First-line Immunotherapy in Patients With Advanced EGFR Mutation-negative Non-small Cell Lung Cancer (NSCLC).","Inclusion Criteria:\n\n1. Participants voluntarily enroll in this study and sign an informed consent form, with good compliance and cooperation with follow-up.\n2. Age is over 18 years old (including 18 years old) and under 75 years old (including 75 years old).\n3. ECOG score: 0-2 points.\n4. Expected survival is no less than 3 months.\n5. Staged as Stage IV according to the TNM system.\n6. Histologically or cytologically confirmed EGFR mutation-negative non-small cell lung cancer.\n7. Has not received systemic antitumor treatment, and is intended to receive monotherapy or combined chemotherapy with a PD-1\u002FPD-L1 inhibitor as first-line treatment.\n8. Normal major organ function, that is, meeting the following criteria: (1) Hematological examination criteria must be met: Hb≥90 g\u002FL; ANC≥1.5×10\\^9\u002FL; PLT≥80×10\\^9\u002FL. (2) Biochemical examination must meet the following criteria: TBIL\\\u003C1.5×ULN; ALT and AST\\\u003C2.5×ULN; serum Cr≤1.25×ULN or endogenous creatinine clearance \\> 45 ml\u002Fmin (Cockcroft-Gault formula).\n9. Women of childbearing age must have taken reliable contraceptive measures and have undergone a pregnancy test (serum or urine) within 7 days before enrollment, with a negative result, and are willing to use appropriate methods of contraception during the trial period and for 8 weeks after the last administration of the trial medication. For men, they must agree to use appropriate methods of contraception during the trial period and for 8 weeks after the last administration of the trial medication or have undergone surgical sterilization.\n\nExclusion Criteria:\n\n1. Have received any of the following treatments:\n\n   1. Previously used any EGFR tyrosine kinase inhibitors;\n   2. Previously received any chemotherapy for lung cancer;\n   3. Previously received any radiotherapy for lung cancer (except palliative radiotherapy for bone metastases);\n   4. Within 4 weeks prior to the first administration of the study drug, the subject had undergone major surgery;\n   5. Within 7 days prior to the first administration of the study drug, used strong inhibitors or inducers of CYP3A4.\n2. Subjects with concurrent other malignant tumors, except for basal cell carcinoma of the skin and in situ cancer.\n3. Subjects with uncontrollable malignant pleural effusion and pericardial effusion.\n4. Subjects allergic to contrast agents for CT and MRI or any subjects who cannot tolerate MRI examination.\n5. As judged by the investigator, any serious or poorly controlled systemic diseases, such as uncontrolled hypertension, active bleeding diathesis, or active infection.\n6. Clinically severe gastrointestinal functional abnormalities that may affect the intake, transport, or absorption of the drug, such as the inability to take oral medication, uncontrollable nausea or vomiting, history of extensive gastrointestinal resection, unresolved recurrent diarrhea, atrophic gastritis, gastric diseases requiring long-term use of proton pump inhibitors, Crohn's disease, ulcerative colitis, etc.\n7. Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis.\n8. Meet any of the following cardiac examination results:\n\n   1. The average of the corrected QT interval (QTcF) obtained from three ECG examinations at rest is \\> 470 msec;\n   2. Resting ECG suggests conduction or ECG morphological abnormalities (such as complete left bundle branch block, third-degree atrioventricular block, second-degree atrioventricular block, and PR interval \\> 250 msec, etc.);\n   3. There are any factors that increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concurrent medication of unexplained sudden death in direct relatives under the age of 40 or prolonged QT interval;\n   4. Left ventricular ejection fraction (LVEF) \\\u003C 50%.\n9. Insufficient bone marrow reserve or organ function, reaching any of the following laboratory limits:\n\n   1. Absolute neutrophil count \\\u003C1.5×10\\^9\u002FL;\n   2. Platelet count \\\u003C100×10\\^9\u002FL;\n   3. Hemoglobin \\\u003C90 g\u002FL (\\\u003C9 g\u002FdL);\n   4. If there is no definite liver metastasis, alanine aminotransferase \\> 3 times the upper limit of normal (ULN); if there is liver metastasis, alanine aminotransferase \\> 5×ULN;\n   5. If there is no definite liver metastasis, aspartate aminotransferase \\>3×ULN; if there is liver metastasis, aspartate aminotransferase \\> 5×ULN;\n   6. If there is no definite liver metastasis, total bilirubin \\> 1.5×ULN; or with Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastasis, total bilirubin \\> 3×ULN;\n   7. Creatinine \\> 1.5×ULN and creatinine clearance \\\u003C50 mL\u002Fmin (calculated by the Cockcroft-Gault formula); creatinine clearance is only required if creatinine \\> 1.5×ULN;\n   8. Serum albumin (ALB) \\\u003C28 g\u002FL.\n10. Active fungal, bacterial, and\u002For viral infections requiring systemic treatment.\n11. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.\n12. History of interstitial lung disease, drug-induced interstitial lung disease, history of radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease.\n13. Subjects who, in the judgment of the investigator, may have poor compliance with the procedures and requirements of the study, such as subjects with a clear history of neurological or mental disorders, currently suffering from mental disorders, etc.\n14. Subjects whom the investigator judges to have any condition that endangers the safety of the subject or interferes with the evaluation of the study.",{"count":279,"type":22},156,[62],"Clinical Trial\n\nThe objective of this clinical trial is to determine whether antidepressant medications, such as olanzapine, in combination with immune checkpoint inhibitors are more effective than the use of immune checkpoint inhibitors alone. The main questions it aims to answer are:\n\nIs the combination therapy of antidepressant medication with immune checkpoint inhibitors more efficacious than the therapy with immune checkpoint inhibitors alone? What medical issues might participants encounter when treated with the combination of antidepressant medication and immune checkpoint inhibitors?\n\nParticipants will:\n\nTake olanzapine in combination with immune checkpoint inhibitors or immune checkpoint inhibitors alone for 2 months.\n\nVisit the clinic for check-ups and tests every two weeks, and have follow-up visits every six weeks after the treatment ends.\n\nKeep a record of their symptoms and disease progression.",[66],{"date":265,"type":40},{"date":285,"type":40},"2024-07-02",{"date":287,"type":22},"2027-05-31",{"name":46,"class":47},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":60,"phases":298,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":7},"100537962","phase-4-early-lumbar-drainage-plus-intrathecal-urokinase-in-severe-aneurysmal-subarachnoid-hemorrhage-ld-ituk-100537962","NCT06284642","Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)","Effectiveness and Safety of Early Lumbar Drainage Plus Intrathecal Urokinase Injection in the Treatment of Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK): a Multicentral Randomized Control Trial","Inclusion Criteria:\n\n* Patient's age ≥ 18 years\n* First occurrence of aneurysmal subarachnoid hemorrhage\n* Patients without any craniotomy treatment before onset\n* Hunt-Hess grade III-V\n* mRS grade 0 or 1 before onset\n* Aneurysm treatment within 48 hours of onset\n* Informed consent given by the subject or guardian\n\nExclusion Criteria:\n\n* Subarachnoid hemorrhage caused by arteriovenous malformation or moyamoya disease or other cerebrovascular disease\n* Patients requiring craniotomy to remove intracranial hematoma\n* modified Fisher Scale grade 0\n* Prothrombin time (PT) and activated partial thromboplastin time (APTT) are greater than 2 times the extended range\n* Absolute contraindications for lumbar puncture (e.g., brain hernia, puncture site infection)\n* Patients with a life expectancy of less than 1 year due to other causes\n* Other concomitant serious diseases that are difficult to treat;\n* Pregnant woman\n* Patients who were known to be allergic to urokinase and excipients or had a history of severe allergy and were deemed unsuitable for inclusion by the investigators\n* Participated in another interventional clinical trial within 30 days before randomization\n* Other reasons deemed unsuitable for study participation by the investigator",{"count":297,"type":22},424,[299],"PHASE4","The LD-ITUK is a multicenter, prospective, randomized, double-blind, blind endpoint, placebo-control design trial. All eligible patients with the diagnosis of severe aSAH will be randomly assigned to the treatment group or the placebo group. Patients in the treatment group will receive standard treatment with the addition of lumbar drainage combined with intrathecal urokinase injection started within 24 hours after aneurysm treatment with 30000 IU urokinase, once a day for 3 consecutive days. Patients in the control group will receive standard treatment with the addition of lumbar drainage combined with intrathecal placebo (0.9%NaCl) injection. The primary outcome measure is favorable functional outcome, defined as a score of 0 to 2 on the modified Rankin Scale (mRS), at 6 months after aneurysmal SAH. Primary outcome will be determined by a member of the Independent Committee on Terminal events.",[302],"Aneurysmal Subarachnoid Hemorrhage",{"date":265,"type":40},{"date":305,"type":40},"2024-03-28",{"date":307,"type":22},"2027-12-30",{"name":46,"class":47},{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":317,"targetDuration":319,"studyType":24,"phases":4,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":48},"100495967","multi-center-registry-cohort-study-on-prognostic-factors-and-prediction-model-construction-in-aneurysmal-sah-100495967","NCT05738083","Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH","Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal Subarachnoid Hemorrhage","PROSAH-MPC","Inclusion Criteria:\n\n* Subarachnoid hemorrhage confirmed by computed tomography (CT);\n* Cerebral angiography (CTA) and digital subtraction angiography (DSA) examination confirming intracranial aneurysm rupture as the cause of the subarachnoid hemorrhage;\n* Blood routine, biochemical function, blood coagulation function, and craniocerebral CT performed within 24 hours of symptom onset;\n* Underwent aneurysm clipping by surgery or endovascular embolization within 72 hours after-onset.\n\nExclusion Criteria:\n\n* Aneurysm rupture bleeding time exceeding 24 hours before hospital admission;\n* Incomplete image data or blood test information;\n* Long-term use of anticoagulant medications such as aspirin or warfarin;\n* Admitted to hospital with active infectious diseases;\n* long-term anticoagulant drugs such as aspirin, wave dimensions;\n* Presence of other intracranial vascular malformations.",{"count":318,"type":22},5000,"12 Months","PROSAH-MPC, a collaborative research project among neurosurgical centers in China, focuses on aneurysmal subarachnoid hemorrhage (aSAH). Its aim is to identify prognostic factors and develop robust prediction models for complications, disability, and mortality in aSAH patients. By leveraging a large, multi-center, prospective cohort design, PROSAH-MPC aims to overcome limitations of past studies and provide a more comprehensive understanding of the disease.",[302],{"date":243,"type":40},{"date":324,"type":40},"2018-10-01",{"date":326,"type":22},"2029-12-30",{"name":46,"class":47},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":60,"phases":337,"briefSummary":338,"conditions":339,"keywords":342,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":48},"100623589","double-dose-third-generation-egfr-tki-plus-bevacizumab-and-intrathecal-chemotherapy-for-refractory-leptomeningeal-metastatic-nsclc-a-phase-ii-study-100623589","NCT07398599","Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study","To Explore the Efficacy and Safety of Double-dose Third-generation EGFR-TKI Combined With Bevacizumab and Intrathecal Chemotherapy in Advanced NSCLC Patients With Progressive Leptomeningeal Metastasis After Prior Standard-dose Third-generation EGFR-TKI Treatment.","Inclusion Criteria\n\n* Aged ≥ 18 years at the time of signing the informed consent form, regardless of gender.\n* Histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC), staged as IV according to the 8th edition of the IASLC TNM classification (2015).\n* Presence of EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation).\n* Leptomeningeal metastasis (LM) progression after standard-dose first-, second-, or third-generation EGFR-TKI treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Adequate major organ function, defined as: hemoglobin (Hb) ≥ 90 g\u002FL, absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL, platelet count (PLT) ≥ 100 × 10\\^9\u002FL, white blood cell count (WBC) ≥ 3.0 × 10\\^9\u002FL and ≤ 10.0 × 10\\^9\u002FL; total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN), alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 × ULN; creatinine clearance ≥ 50 ml\u002Fmin (for patients with liver metastases, TBIL ≤ 3.0 × ULN, ALT and AST ≤ 5.0 × ULN); activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≤ 1.5 × ULN.\n* At least 21 days since the last radiotherapy (including whole-brain radiotherapy or local radiotherapy for brain metastases).\n* Expected survival ≥ 3 months.\n* Ability to swallow oral medications (or receive crushed medications via gastrostomy tube if unable to swallow).\n* For women: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) within 14 days prior to enrollment, during the study, and for 3 months after the last study drug administration.\n* For men: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) during the study and for 3 months after the last study drug administration.\n* Voluntary participation, signed informed consent, and willingness to comply with study procedures and protocols.\n\nExclusion Criteria\n\n* Major surgery within 4 weeks prior to the start of study treatment, or need for major surgery during the study.\n* Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).\n* Active bacterial\u002Ffungal\u002Fviral infections requiring intravenous antibiotic therapy.\n* Drug-induced pneumonitis or interstitial lung disease, or evidence of clinically significant active pulmonary disease.\n* Severe cardiovascular events within 6 months prior to enrollment, including cerebrovascular accident, deep vein thrombosis, or pulmonary embolism.\n* Significant cardiovascular disease, such as New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, symptomatic arrhythmias requiring treatment, or corrected QT interval (QTcF) \\> 470 ms on consecutive electrocardiograms.\n* History of other systemic malignant tumors within the past 5 years (except for cured basal cell carcinoma, carcinoma in situ of the cervix, and ovarian cancer).\n* Use of drugs or supplements known to be strong inducers of CYP3A4.\n* Known severe allergy to any study drug or its excipients.\n* Pregnancy, lactation, or refusal of effective contraception by patients of childbearing potential.\n* History of definite neurological or psychiatric disorders (including epilepsy and dementia).\n* Other conditions deemed unsuitable for enrollment by the investigator.","99 Years",{"count":59,"type":22},[114],"The goal of this clinical trial is to explore the efficacy and safety of double-dose third-generation EGFR-TKI combined with bevacizumab and intrathecal chemotherapy in treating advanced non-small cell lung cancer (NSCLC) patients with leptomeningeal metastasis that progressed after prior standard-dose third-generation EGFR-TKI treatment. It also aims to investigate the correlation between cerebrospinal fluid genetic characteristics and prognosis as well as subsequent efficacy prediction in patients with leptomeningeal metastasis after resistance to standard-dose third-generation EGFR-TKI. The main questions it intends to answer are:\n\nDoes this combined treatment regimen improve leptomeningeal metastasis response rate (LM-ORR) evaluated by RANO-LM? What adverse events occur in patients during the treatment with this combined regimen? Researchers will conduct a single-arm phase II prospective study to assess the effectiveness and safety of the combined treatment, without a control group comparison.\n\nParticipants will:\n\nReceive double-dose third-generation EGFR-TKI (osimertinib 160mg qd, furmonertinib 160mg qd, or almonertinib 220mg qd) + intrathecal pemetrexed (induction phase: 10mg twice a week for 4 weeks; maintenance phase: 10mg once a week for 4 weeks; consolidation phase: 30mg every 4 weeks until disease progression or intolerable toxicity) + bevacizumab 7.5mg\u002Fkg.\n\nUndergo screening assessments within 28 days before enrollment, including tumor imaging, laboratory tests, and cerebrospinal fluid examination.\n\nDuring the treatment period, conduct regular checkups and tests (such as blood routine, blood biochemistry, electrocardiogram, and imaging examinations) according to the protocol (once every 4 weeks in the first two treatment cycles, then once every 8 weeks).\n\nComplete quality of life assessment using the QLQ-C30 scale every 4 weeks and record changes in neurological symptoms and ECOG scores.",[340,341],"Leptomeningeal Metastasis","Lung Neoplasms, Non-Small Cell Lung Cancer",[340,343],"non-small cell lung cancer","2026-04-21",{"date":346,"type":40},"2026-04-23",{"date":348,"type":40},"2026-02-15",{"date":307,"type":22},{"name":46,"class":47},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":361,"conditions":362,"keywords":366,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":48},"100578037","analysis-of-influencing-factors-of-high-order-aberrations-of-smile-with-lenticule-retained-100578037","NCT06806085","Analysis of Influencing Factors of High-Order Aberrations of SMILE With Lenticule Retained","Analysis of Influencing Factors of High-Order Aberrations of Small Incision Lenticule Extraction With Lenticule Retained","Inclusion Criteria:\n\n1. Age ≥ 18 years, gender unrestricted;\n2. Equivalent spherical refraction ≤ -10.0D, corrected distance visual acuity ≥ 1.0, myopia stable for ≥ 2 years, and no contact lens wear for at least 2 weeks;\n3. The patient voluntarily participates in this study, signs the informed consent form, and agrees to follow up according to the study plan;\n4. Predicted postoperative residual corneal stromal thickness ≥ 280 micrometers.\n\nExclusion Criteria:\n\n1. Subclinical keratoconus, keratoconus, moderate to severe corneal opacities or scars, and other ocular conditions;\n2. Diabetes, keloid-prone constitution, autoimmune and connective tissue diseases, etc.;\n3. Severe mental disorders such as generalized anxiety disorder, panic disorder, depression, schizophrenia, and bipolar disorder; inability to cooperate with physicians;\n4. Refusal to participate in the study.","45 Years",{"count":360,"type":22},33,"Analysis of Influencing Factors of High-Order Aberrations of SMILE with Lenticule Retained",[363,364,365],"Small-incision Lenticule Extraction (SMILE) Surgery","Corneal Higher-order Wavefront Aberrations","Residual Lenticule",[365,364,367],"Small-incision Lenticule Extraction",{"date":369,"type":40},"2026-04-22",{"date":371,"type":40},"2024-10-31",{"date":373,"type":22},"2026-10-31",{"name":46,"class":47},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":358,"enrollmentInfo":382,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":384,"conditions":385,"keywords":391,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":48},"100567556","study-on-the-diagnostic-efficacy-of-icl-selection-and-prediction-depth-model-based-on-eye-images-100567556","NCT06669728","Study on the Diagnostic Efficacy of ICL Selection and Prediction Depth Model Based on Eye Images","Diagnostic Efficacy of Deep Neural Network Algorithm Based on Preoperative Scheimpflug-based Anterior Segment Image for Implantable Collamer Lens Selection and Prediction","Inclusion Criteria:\n\n1. Aged 18-45 years ;\n2. Myopia, with or without astigmatism, annual diopter change ≤ 0.50 D for 2 consecutive years ;\n3. Anterior chamber depth ≥ 2.80 mm ;\n4. Corneal endothelial cell count ≥ 2000 \u002F mm2, stable cell morphology ;\n5. There were no other ocular diseases that significantly affected vision and \u002F or systemic organic lesions that affected surgical recovery.\n\nExclusion Criteria:\n\n1. There were no other ocular diseases that significantly affected vision and \u002F or systemic organic lesions that affected surgical recovery;\n2. Have a history of corneal refractive surgery or intraocular surgery ;\n3. Corneal endothelial cell count is low ;\n4. Those with systemic diseases ;\n5. Lactating or pregnant women.",{"count":383,"type":22},326,"To evaluate the diagnostic efficacy of deep learning network model in implantable collamer lens selection and prediction in a multicenter cross-sectional study",[386,387,388,389,390],"Posterior Chamber Phakic Intraocular Lens","Vault","Deep Neural Network","Myopia","Anterior Chamber Angle",[386,387,388],{"date":393,"type":40},"2026-04-24",{"date":395,"type":40},"2021-01-02",{"date":397,"type":22},"2027-08-31",{"name":46,"class":47},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":358,"enrollmentInfo":406,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":408,"conditions":409,"keywords":413,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":48},"100531832","diagnostic-efficacy-of-cnn-in-predicting-intraoperative-complications-and-postoperative-outcomes-in-smile-100531832","NCT06204926","Diagnostic Efficacy of CNN in Predicting Intraoperative Complications and Postoperative Outcomes in SMILE","Diagnostic Efficacy of Convolutional Neural Network Based Algorithm in Predicting Intraoperative Complications and Postoperative Outcomes in Small Incision Lenticule Extraction","Inclusion Criteria:\n\n* A condition in which the spherical equivalent refractive error of an eye is ≤-0.50 D when ocular accommodation is relaxed;\n* Age ≥18 years;\n* Spherical equivalent (SE) ≥-10.0D;\n* Corrected distance visual acuity (CDVA) ≥16\u002F20;\n* Stable myopia for at least 2 years;\n* No contact lenses wearing for at least 2 weeks.\n\nExclusion Criteria:\n\n* The presence or history of eye conditions other than myopia and astigmatism, such as keratoconus or external eye injury;\n* A history of eye surgery;\n* The presence or history of systemic diseases.",{"count":407,"type":22},1250,"To evaluate the diagnostic efficiency of the neural network in predicting complications of Small Incision Lenticule Extraction in a multi-center cross-sectional study.",[410,363,411,412],"Deep Convolutional Neural Network","Intraoperative Complications","Postoperative Outcomes",[414,411,410,412],"femtosecond laser small-incision lenticule extraction",{"date":393,"type":40},{"date":417,"type":40},"2021-06-15",{"date":419,"type":22},"2027-12",{"name":46,"class":47},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":60,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":438,"leadSponsor":440,"locationsCount":4},"100619605","the-underlying-neural-mechanism-of-tms-in-improving-the-imbalance-of-microbiota-brain-gut-axis-in-alzheimer-s-disease-population-100619605","NCT07346794","The Underlying Neural Mechanism of TMS in Improving the Imbalance of \"Microbiota-brain-gut Axis\" in Alzheimer 's Disease Population","Inclusion Criteria:\n\n* Dementia Patients: Conformed to internationally recognized diagnostic criteria for dementia (e.g., DSM-5, NINCDS-ADRDA)\n* Diagnosed through clinical evaluation, neuropsychological scale assessments, and relevant examinations\n* Aged ≥50 years and residing in Nanchang, Jiangxi\n* With dementia-negative family history, no severe psychiatric or neurological disorders\n* No history of major systemic diseases.\n\nExclusion Criteria:\n\n* Unable to cooperate with all required examinations, intervention procedures, and sample collection during the study.",{"count":428,"type":22},400,[114],"What is this study about? This study focuses on Alzheimer's Disease (AD), a common neurodegenerative disease that affects memory, thinking, and daily life. We aim to explore whether a non-invasive treatment called Repetitive Transcranial Magnetic Stimulation (rTMS) can improve AD symptoms by regulating the \"gut-brain-intestine axis\" - a connection between gut bacteria, the brain, and the intestines.\n\nWho can participate?\n\n* \\*\\*AD patients\\*\\*: Aged 50-80, diagnosed with mild to moderate AD (MMSE score 18-27, MoCA score 10-26), with stable condition for at least 6 months, and able to cooperate with tests and treatment.\n* \\*\\*Healthy controls\\*\\*: Aged 50-80, with normal cognitive function (MMSE ≥28, MoCA ≥27), no AD family history, and matched in age and gender with AD patients.\n\nThose with epilepsy, severe mental illness, recent use of antibiotics\u002Fprobiotics, or inability to complete MRI scans are not eligible.\n\nWhat will participants experience?\n\n* \\*\\*AD patients\\*\\*: Will be randomly divided into two groups. Both groups will receive 4 weeks of treatment (5 days\u002Fweek) with a helmet-like device. One group gets real rTMS (safe magnetic stimulation to the brain), and the other gets sham stimulation (no effective magnetic field, but same sound\u002Ffeel).\n* \\*\\*Healthy controls\\*\\*: No treatment, but will complete the same tests as AD patients.\n* \\*\\*Tests during the study\\*\\*: Cognitive assessments (memory, thinking skills via questionnaires), stool\u002Fblood sample collection (to check gut bacteria and body markers), and MRI scans (to look at brain structure\u002Ffunction) at baseline, 1 month, 3 months, 6 months, and 1 year.\n\nWhat are the potential benefits?\n\n* Free rTMS treatment (for AD patients), free MRI scans (valued at 700 RMB), and a 200 RMB subsidy.\n* Free health checks (gut bacteria analysis, metabolic tests) and cognitive evaluations to understand personal health status.\n* Contribution to developing new AD treatments that may help future patients.\n\nIs it safe? rTMS is a clinically proven safe technique. Possible mild side effects (headache, scalp irritation) usually go away on their own. Sample collection (stool\u002Fblood) and MRI scans are non-invasive or minimally invasive. A professional team will monitor participants throughout to handle any issues.\n\nFor healthcare providers This is a multicenter, randomized, double-blind sham-controlled study (200 AD patients, 200 healthy controls). The primary goal is to explore rTMS's mechanism via the gut-brain-intestine axis, with MoCA score changes (6 months post-treatment) as the main outcome. It integrates multi-omics and neuroimaging data to provide evidence for AD's non-drug treatment.",[432,433],"Alzheimer's Disease","rTMS Stimulation","2026-04-04",{"date":436,"type":40},"2026-04-09",{"date":344,"type":22},{"date":439,"type":22},"2030-09-30",{"name":46,"class":47},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":82,"enrollmentInfo":447,"targetDuration":4,"studyType":60,"phases":448,"briefSummary":449,"conditions":450,"keywords":451,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":48},"100632542","comparative-study-on-the-safety-and-efficacy-of-using-accusafe-transseptal-guidewire-versus-traditional-transseptal-needle-for-transseptal-puncture-in-non-or-free--guidance-100632542","NCT07515040","Comparative Study on the Safety and Efficacy of Using AccuSafe Transseptal Guidewire Versus Traditional Transseptal Needle for Transseptal Puncture in non-or Free- Guidance","Inclusion Criteria:\n\n① Age 18-75 years (inclusive); ② Clinically diagnosed with atrial fibrillation, indicated for radiofrequency ablation, and scheduled for catheter ablation; ③ Voluntarily agrees to participate in the trial and has signed informed consent; ⑤ Willing to comply with the trial requirements and complete the required follow-up. (All patients must have normal fossa ovalis anatomy confirmed by preoperative echocardiography; complex cases such as patent foramen ovale and atrial septal aneurysm are excluded)\n\nExclusion Criteria:\n\n① History of patent foramen ovale, atrial septal defect, post-atrial septal defect closure, post-valve replacement, or post-permanent pacemaker implantation; ② Intraoperative anatomical abnormalities requiring conversion to X-ray guidance-these patients will be withdrawn from the study and treated as dropouts.",{"count":144,"type":22},[114],"1. Research Title: Comparative study on the safety and effectiveness of AccuSafe transseptal guidewire versus traditional transseptal needle for transseptal puncture without X-ray guidance\n2. Research Objective: This study aims to compare the safety and effectiveness of the AccuSafe guidewire with the traditional transseptal needle in performing X-ray-free transseptal puncture under ICE guidance. Through this study, we hope to provide a safer and more effective method for transseptal puncture, reduce X-ray exposure for both patients and physicians, improve surgical success rates, and decrease the incidence of complications.\n3. Study Design: Interventional clinical study\n4. Study Subjects: Patients with atrial fibrillation scheduled for catheter ablation at the Second Affiliated Hospital of Nanchang University from February 2025 to November 2025.\n5. Sample Size: N=144 patients, randomly assigned using a computer-generated random number table to the AccuSafe guidewire group (n=72) or the traditional TSP needle group (n=72) at a 1:1 ratio.\n6. Inclusion and Exclusion Criteria:\n\n   Inclusion Criteria: ① Age 18-75 years (inclusive); ② Clinically diagnosed with atrial fibrillation, indicated for radiofrequency ablation, and scheduled for catheter ablation; ③ Voluntarily agrees to participate in the trial and has signed informed consent; ⑤ Willing to comply with the trial requirements and complete the required follow-up. (All patients must have normal fossa ovalis anatomy confirmed by preoperative echocardiography; complex cases such as patent foramen ovale and atrial septal aneurysm are excluded.) Exclusion Criteria: ① History of patent foramen ovale, atrial septal defect, post-atrial septal defect closure, post-valve replacement, or post-permanent pacemaker implantation; ② Intraoperative anatomical abnormalities requiring conversion to X-ray guidance-these patients will be withdrawn from the study and treated as dropouts.\n7. Observational Indicators:(1) Baseline Data: Age, sex, BMI, type of atrial fibrillation, CHA2DS2-VASc score, left atrial diameter, ejection fraction, and the proportion of patients with diabetes, hypertension, congestive heart failure, stroke\u002FTIA, and coronary artery disease.(2) Surgical Data: First puncture success rate, surgical complications, total procedure time, X-ray exposure, total TSP time, number of punctures required to achieve left atrial access, and width of atrial septal shunt at the end of ablation.\n8. Statistical Analysis: Data will be analyzed using IBM SPSS Statistics 27.0. Normally distributed measurement data will be expressed as mean ± standard deviation, and comparisons between two independent samples will be performed using t-tests. Categorical data will be expressed as frequency and percentage, with comparisons conducted using the chi-square test. Two-sided P\\\u003C0.05 will be considered statistically significant.",[148],[452],"Atrial Fibrillation","2026-03-31",{"date":455,"type":40},"2026-04-07",{"date":457,"type":40},"2025-02-26",{"date":459,"type":22},"2027-02-26",{"name":46,"class":47},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":82,"enrollmentInfo":468,"targetDuration":4,"studyType":60,"phases":470,"briefSummary":471,"conditions":472,"keywords":476,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":48},"100613880","phase-4-the-impact-of-semaglutide-compared-to-energy-restriction-on-type-2-diabetes-100613880","NCT07272343","The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes","A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular Mechanisms","Inclusion Criteria:\n\n1. Age 18-75 years;\n2. BMI≥25 kg\u002Fm²;\n3. Diagnosed as type 2 diabetes mellitus patients according to the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)\";\n4. HbA1c≤8.5%;\n5. Duration of diabetes ≤3 months, and no use of antihyperglycemic drugs;\n6. Willing to participate in this study, and after full informed consent, agrees to strictly follow the treatment plan and promises to attend follow-up visits on time, and signs the informed consent form.\n\nExclusion Criteria:\n\n1. BMI \\\u003C 25 kg\u002Fm²;\n2. Age \\\u003C 18 years, or \\> 75 years;\n3. History of type 1 diabetes, acute pancreatitis, or diabetes secondary to pancreatectomy;\n4. History of bariatric surgery or planned bariatric surgery, or currently attempting weight loss within the past 3 months, or use of weight-loss medications within the past 3 months;\n5. Use of GLP-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, or other related drugs within the past 3 months;\n6. Pregnant or breastfeeding women, or those planning to conceive during the study period;\n7. Patients with severe diseases of important organ systems, such as severe cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, renal insufficiency, hematologic diseases, neurological diseases, or malignancies;\n8. Personal or family history of medullary thyroid carcinoma;\n9. Patients with severe mental disorders or communication barriers that prevent accurate understanding of the study content and compliance with the trial procedures.",{"count":469,"type":22},100,[299],"To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.",[473,474,475],"Type 2 Diabetes Mellitus (T2DM)","Semaglutide","Caloric Restriction",[477,478,475],"Type 2 Diabetes Mellitus","semaglutide",{"date":480,"type":40},"2026-04-02",{"date":482,"type":40},"2023-02-10",{"date":484,"type":22},"2026-07-01",{"name":46,"class":47},{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":492,"enrollmentInfo":493,"targetDuration":4,"studyType":60,"phases":495,"briefSummary":496,"conditions":497,"keywords":501,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":510,"locationsCount":4},"100623834","efficacy-and-safety-evaluation-of-remote-ischemic-adaptation--intermittent-pressure-stimulation--in-the-treatment-of-insomnia-after-stroke-100623834","NCT07401784","Efficacy and Safety Evaluation of Remote Ischemic Adaptation ( Intermittent Pressure Stimulation ) in the Treatment of Insomnia After Stroke","Inclusion Criteria:\n\n* Age 18-80 years old ;\n* In line with the diagnostic criteria of ischemic stroke, with reference to the ' Chinese guidelines for the diagnosis and treatment of acute ischemic stroke ' diagnosed ischemic stroke ;\n* Despite adequate sleep opportunities, patients still have difficulty in falling asleep or maintaining sleep, staying asleep at least 3 times a week for at least 3 months, which leads to pain or impaired daytime function.\n* PSQI score ≥ 6 and ISI score ≥ 8 ;\n* All research contents have been understood and informed consent has been signed.\n\nExclusion Criteria:\n\n* Insomnia before stroke ;\n* Patients with mental disorders, bipolar disorder or depression, generalized anxiety disorder and other mental disorders ;\n* Patients were pregnant or lactating women ;\n* Other reasons identified by the researchers are not suitable for patients ;","80 Years",{"count":494,"type":22},40,[114],"The incidence of post-stroke depression is high, which will affect the rehabilitation of neurological function, damage cognitive function, and increase the risk of subsequent stroke recurrence. The guidelines recommend that in addition to antiplatelet, blood pressure control, lipid-lowering and other treatments, secondary prevention of post-stroke depression should also be strengthened. Moreover, after the occurrence of post-stroke depression, methods such as medication and psychotherapy have their own limitations, such as potential adverse drug reactions and limited psychotherapy. Therefore, it is necessary to pay attention to the prevention of post-stroke depression.\n\nThe remote ischemic adaptation therapy applied in our study is a safe, non-invasive and convenient physical therapy. By transiently and repeatedly applying ischemia-reperfusion stimulation to both upper arms, it induces a systemic protective response, improves the brain 's tolerance to ischemia and hypoxia, and exerts a protective effect on multiple organs such as the brain and heart. The RIC therapeutic instrument has been national patented and has been maturely applied to the prevention and treatment of acute cerebral infarction, which can promote the rehabilitation of neurological function. In addition, it also has certain curative effect in the treatment of cerebrovascular stenosis, refractory hypertension, depression, insomnia, anxiety and so on.",[498,499,500],"Cerebral Apoplexy","Depression Anxiety Disorder","Cerebrovascular Disease",[502,503,499,500],"Remote ischemic adaptation technology","cerebral apoplexy","2026-02-03",{"date":506,"type":40},"2026-02-10",{"date":508,"type":22},"2026-01-27",{"date":307,"type":22},{"name":46,"class":47},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":518,"enrollmentInfo":519,"targetDuration":4,"studyType":60,"phases":521,"briefSummary":522,"conditions":523,"keywords":526,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":48},"100619699","safety-and-efficacy-of-platelet-rich-plasma-combined-with-compound-betamethasone-in-arthroscopic-surgery-for-rotator-cuff-injury-with-shoulder-adhesion-a-prospective-multicenter-randomized-controlled-trial-100619699","NCT07348016","Safety and Efficacy of Platelet-Rich Plasma Combined With Compound Betamethasone in Arthroscopic Surgery for Rotator Cuff Injury With Shoulder Adhesion: A Prospective, Multicenter, Randomized Controlled Trial","PRP+CB for RC","Inclusion Criteria:\n\nAge between 18 and 70 years.\n\nClinical and MRI diagnosis of full-thickness rotator cuff tear.\n\nPresence of shoulder stiffness\u002Fadhesion defined as passive range of motion less than 100° in forward flexion and\u002For less than 10° in external rotation (or according to your specific definition).\n\nScheduled for arthroscopic rotator cuff repair and capsular release.\n\nWilling and able to provide written informed consent.\n\nWilling to comply with all study procedures and follow-up visits.\n\nExclusion Criteria :\n\nMassive, irreparable rotator cuff tear.\n\nSevere glenohumeral osteoarthritis (Grade III or IV according to Samilson-Prieto classification).\n\nHistory of shoulder infection, fracture, or previous surgery on the affected shoulder.\n\nKnown allergy or contraindication to betamethasone, local anesthetics, or components of PRP preparation.\n\nSystemic inflammatory arthritis (e.g., rheumatoid arthritis).\n\nCoagulation disorders or use of anticoagulants that cannot be safely suspended perioperatively.\n\nPregnancy or lactation.\n\nParticipation in another clinical trial within the past 3 months.\n\nAny medical or psychiatric condition that, in the investigator's opinion, would compromise patient safety or compliance with the study protocol.","70 Years",{"count":520,"type":22},70,[114],"Background: Patients undergoing arthroscopic surgery for rotator cuff tears with shoulder adhesion often experience significant postoperative pain and stiffness. This study investigates whether adding a long-acting local anesthetic (Liposomal Bupivacaine) to a standard anti-inflammatory steroid injection (Compound Betamethasone) during surgery can improve outcomes.\n\nMethods: This is a prospective, randomized, double-blind, controlled trial. Approximately 70 eligible adult patients will be randomly assigned to one of two groups: (1) the Combination Group, receiving an intra-articular injection of Liposomal Bupivacaine plus Compound Betamethasone after surgery, or (2) the Control Group, receiving Compound Betamethasone alone. Patients and outcome assessors will not know the group assignment.\n\nWhat participants will do: All participants will receive standard arthroscopic rotator cuff repair and adhesion release. They will be followed for 12 months after surgery, with assessments at multiple time points (from hours to months post-op) to measure pain levels, shoulder function, range of motion, and tendon healing via MRI.\n\nMain Goals: The primary goal is to compare the improvement in UCLA shoulder scores between the two groups at 12 months. Secondary goals include comparing pain scores, other functional scores (Constant-Murley), joint mobility, MRI findings, and safety (complication rates).",[524,525],"Rotator Cuff Injuries","Adhesions",[527,528,529,124,530,531],"Platelet-Rich Plasma","Compound Betamethasone","Arthroscopy","Shoulder","Stiffness","2026-01-08",{"date":534,"type":40},"2026-01-16",{"date":536,"type":40},"2025-08-01",{"date":538,"type":22},"2028-12-01",{"name":46,"class":47},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":518,"enrollmentInfo":547,"targetDuration":4,"studyType":60,"phases":548,"briefSummary":549,"conditions":550,"keywords":552,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":562,"locationsCount":48},"100615915","phase-1-preliminary-clinical-study-of-the-effectiveness-and-safety-of-ocular-surface-microbiota-transplantation-in-the-treatment-of-dry-eye-disease-100615915","NCT07298811","Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment of Dry Eye Disease","Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment of Dry Eye Disease: a Randomized, Single-blind,-Controlled Trial.","Inclusion Criteria:\n\n* Dry Eye Patient Group:\n\n  * Aged 18 to 70 years, male or female.\n  * Meets the diagnostic criteria for moderate to severe mixed dry eye according to the Expert Consensus on Dry Eye (2020), including:\n  * At least one subjective symptom (e.g., dryness, foreign body sensation, burning, fatigue, discomfort, redness, or vision fluctuation).\n  * Fluorescein tear film break-up time (FBUT) ≤ 5 seconds.\n  * Willing and able to actively cooperate with the prescribed course of standard dry eye medications and ocular surface microbiota transplantation therapy for the study duration.\n  * Voluntarily agrees to participate and signs the informed consent form.\n* Healthy Donor Group:\n\n  * A family member of a participating subject.\n  * Aged 18 to 50 years.\n  * Normal ocular surface structure and function, with no ocular diseases or related symptoms, and good visual function.\n\nExclusion Criteria:\n\n* Dry Eye Patient Group:\n\n  * History of systemic chronic diseases (e.g., uncontrolled diabetes, autoimmune disorders).\n  * Current or past history of eyelid abnormalities, conjunctival disease, or lacrimal duct obstruction.\n  * History of any ocular surgery or regular wear of corneal contact lenses.\n  * Active infection in the eye(s) or any other part of the body.\n  * History of multiple episodes of viral keratitis or presence of significant neurotrophic keratitis.\n  * Any other condition deemed by the investigator to be unsuitable for participation.\n* Healthy Donor Group:\n\n  * Known infectious diseases (e.g., HIV, Hepatitis B).\n  * Signs or symptoms suggestive of active ocular surface infection or other viral infections.\n  * Current or past history of eyelid, conjunctival, or lacrimal duct diseases.\n  * Use of systemic medications (including antibiotics), traditional Chinese herbal medicine, or probiotic supplements within 1 month prior to screening.\n  * Pregnancy, lactation, or any other condition that may potentially affect the study outcomes.",{"count":494,"type":22},[86,62],"Evaluate the efficacy and safety of ocular surface microbiota transplantation as an adjunctive therapy for dry eye, and explore its impact on the structure of the ocular surface microbiota.",[551],"Dry Eye",[553,554,555],"dry eye","ocular surface diseases","Microbiota transplantation","2025-12-20",{"date":558,"type":40},"2025-12-23",{"date":560,"type":40},"2025-10-01",{"date":484,"type":22},{"name":46,"class":47},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":18,"minAge":570,"maxAge":56,"enrollmentInfo":571,"targetDuration":4,"studyType":60,"phases":573,"briefSummary":574,"conditions":575,"keywords":577,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":581,"leadSponsor":583,"locationsCount":48},"100615916","phase-2-clinical-efficacy-and-mechanism-exploration-of-mr-61-in-delaying-the-progression-of-myopia-100615916","NCT07298824","Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia","Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n1. Myopia is defined as spherical equivalent (SE) ≤ -0.5D.\n2. Aged between 3 and 18 years, with no restriction on gender.\n3. Cylinder power ≤ 1.50D; anisometropia of SE between both eyes ≤ 1.50D.\n4. The subject has sufficient compliance with the study follow-up; the subject or their guardian has the intention to receive treatment and has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of other concomitant ocular diseases;\n2. Abnormal findings on clinical slit-lamp examination;\n3. Existence of amblyopia, manifest strabismus, esotropia, or other congenital ocular diseases;\n4. Individuals with abnormal intraocular pressure or abnormal axial length of the eye;\n5. Either or both parents having a spherical equivalent (SE) ≤ -6.00D;\n6. Other conditions inconsistent with this study.","3 Years",{"count":572,"type":22},164,[62],"To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).",[576],"Myopia Progressing",[578],"Myopia,Probiotics,Gut microbiota",{"date":558,"type":40},{"date":560,"type":40},{"date":582,"type":22},"2027-07-01",{"name":46,"class":47},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":590,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":60,"phases":594,"briefSummary":595,"conditions":596,"keywords":599,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":4},"100615291","phase-4-intensive-cholesterol-lowering-within-24-hours-of-pci-perioperative-period-100615291","NCT07290699","Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period","INtensive Cholesterol-Lowering With recatIcimab combiNation in Emergency PCI for Acute Myocardial Infarction: A Randomized Controlled Trial","INCLINE-AMI","Inclusion Criteria:\n\n* Age ≥18 years;\n* Meet the definition of acute myocardial infarction according to the \"2019 Guidelines for the Diagnosis and Treatment of Acute ST-Segment Elevation Myocardial Infarction\", including STEMI and NSTEMI with onset \\\u003C24 hours;\n* Able to understand and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Severe mental disorders that prevent the expression of consent;\n* Severe heart failure (Killip class III or IV) or cardiogenic shock;\n* According to the investigator's judgment, the presence of significant other abnormal signs, laboratory findings, or clinical conditions (such as tumors, shock, liver or kidney failure, etc.) that make participation unsuitable;\n* Investigator's judgment that the subject cannot complete long-term follow-up;\n* Intolerance to statins or cholesterol absorption inhibitors;\n* Intolerance to injections;\n* Subjects who received PCSK9 inhibitor treatment or participated in other PCSK9 inhibitor studies within 4 months before randomization;\n* Pregnant women.",{"count":593,"type":22},2442,[299],"This project team is conducting a multicenter randomized controlled study, aiming to administer PCSK9 inhibitors subcutaneously as early as possible within 24 hours during the perioperative period of AMI (included \\\u003C24h STEMI and NSTEMI), and subsequently once every 12 weeks for a total of 6 months, followed by step-down therapy according to guideline-recommended lipid-lowering strategies based on LDL-C target levels. The study will evaluate changes in blood lipids and inflammatory markers during hospitalization and at follow-up visits at 1, 3, 6, 9, and 12 months, as well as the incidence of MACE events. Safety will also be assessed, including liver enzymes, kidney function, and other adverse reactions. Compared with conventional treatment, the study will test efficacy and ultimately clarify that early combined use of PCSK9 inhibitors during the perioperative period of AMI patients can safely and effectively reduce LDL-C, control systemic inflammatory responses, and improve the incidence of MACE events.",[597,598],"STEMI - ST Elevation Myocardial Infarction","NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)",[600,601,602],"Acute myocardial infarction","Recaticimab","PCSK9 inhibitor","2025-12-16",{"date":605,"type":40},"2025-12-18",{"date":607,"type":22},"2026-01-01",{"date":609,"type":22},"2028-08-30",{"name":46,"class":47},""]